Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer
Status:
Recruiting
Trial end date:
2024-05-25
Target enrollment:
Participant gender:
Summary
This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab
in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of
this drug combination will be assessed to see what effect this treatment has on this patient
population.